期刊
ENDOCRINOLOGY
卷 151, 期 4, 页码 1713-1722出版社
ENDOCRINE SOC
DOI: 10.1210/en.2009-0813
关键词
-
资金
- National Institutes of Health [R01 DE14680]
- Mayo Foundation
Local release of TGF-beta during times of high bone turnover leads to elevated levels within the bone microenvironment, and we have shown that TGF-beta suppresses osteoclast apoptosis. Therefore, understanding the influences of TGF-beta on bone resorbing osteoclasts is critical to the design of therapies to reduce excess bone loss. Here we investigated the mechanisms by which TGF-beta sustains suppression of osteoclast apoptosis. We found TGF-beta rapidly increased leukemia inhibitory factor (LIF) expression and secretion by phosphorylated mothers against decapentaplegic-dependent and -independent signaling pathways. TGF-beta also induced suppressor of cytokine signaling 3 (SOCS3) expression, which was required for TGF-beta or LIF to promote osteoclast survival by. Blocking LIF or SOCS3 blocked TGF-beta promotion of osteoclast survival, confirming that LIF and SOCS3 expression are necessary for TGF-beta-mediated suppression of osteoclast apoptosis. Investigation of the mechanisms by which LIF promotes osteoclast survival revealed that LIF-induced expression of Bcl-X-L and repressed Bcl-2 interacting domain expression by activating MAPK kinase, AKT, and nuclear factor-kappa B pathways. Suppression of Janus kinase/signal transducer and activator of transcription signaling further increased Bcl-X-L expression and enhanced osteoclast survival, supporting that this pathway is not involved in prosurvival effects of TGF-beta and LIF. These data show that TGF-beta coordinately induces LIF and SOCS3 to promote prosurvival signaling. This alters the ratio of prosurvival Bcl2 family member Bcl-X-L to proapoptotic family member Bcl-2 interacting domain, leading to prolonged osteoclast survival. (Endocrinology 151: 1713-1722, 2010)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据